Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Gastrointestinal Metabolic Disorders South Africa

Alizyme licenses Colal-Pred to Norgine

This article was originally published in Scrip

Executive Summary

Alizyme Therapeuticshas granted Norginethe exclusive rights to Colal-Pred (prednisolone sodium metasulfobenzoate), for the treatment of ulcerative colitis, in Europe, South Africa, Australia and New Zealand. Norgine will now develop and market Colal-Pred in the areas and will pay Alizyme €2 million up-front, with the possibility of milestone payments of up to €41 million. Norgine will cover all commercialisation costs and will pay double-digit royalty sales to Alizyme.

Table

View full table

Topics

Related Companies

Tags:
Gastrointestinal Metabolic Disorders South Africa
Latest Headlines

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Humira Market Erosion Is Continuing As Expected, AbbVie Says

Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

Analysis: Novo And Lilly Make Their Money Work

See All
UsernamePublicRestriction

Register

SC031722

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By